

Preliminary Amendment

Q68625

4. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of myasthenia gravis, comprising a indoloylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

5. A drug for treating or preventing progress of symptoms, through inhibiting death of neurons, of brain ischemia and delayed neuronal death (DND), comprising a indoloylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

6. A drug for treating or preventing progress of symptoms, through inhibiting death of myocardial cells, of ischemic heart disease, viral myocarditis, autoimmune myocarditis, myocardial disorders/cell death due to hypertrophic heart and heart failure, or arrhythmogenic right ventricular cardiomyopathy, comprising a indoloylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

7. A drug for treating or preventing progress of symptoms, through inhibiting death of hepatic cells, of alcoholic hepatitis or viral hepatitis, comprising a indoloylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

8. A drug for treating or preventing progress of symptoms, though inhibiting death of renal cells, or renal diseases, comprising a indoloylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Preliminary Amendment

Q68625

9. A drug for treating or preventing progress of symptoms, through inhibiting excessive death of T-cells, of acquired immunodeficiency syndrome (AIDS), comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

10. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of inflammatory skin disorders, alopecia, or graft versus host disease (GVH), comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

M 11. A drug for treating or preventing disorders or side effects, through inhibiting cell death, of disorders due to radiation or drugs, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

12. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of sepsis, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

13. A drug for treating or preventing progress of symptoms, through inhibiting death of cells derived from bone marrow, of steomyelo-dysplasia, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

14. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of insulin dependent diabetes, comprising a indolylmaleimide derivative represented by the above formula (II) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Preliminary Amendment

Q68625

15. A drug for treating or preventing progress of symptoms, through inhibiting death of neurons, of prion diseases, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

16. A drug for treating or preventing functional deficiency of transplanted organs, tissues or cells at transplantation of organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

17. A preservative for organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

---

REMARKS

Claims 2-17 have been amended to make them dependent on Claim 1.

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,

SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860  
MXB/slb  
Date: February 20, 2002

*for John Callahan Reg. No. 32,607*  
Mark Boland  
Registration No. 32,197